News Hub | News Direct

All Industries


Article thumbnail News Release

Intriquip Instruments Now Offering Bowa Electrosurgical Systems in Canada

Rev Up Marketers

Intriquip Instruments Inc., a leading Canadian veterinary and medical equipment distributor, is proud to supply advanced electrosurgical systems and accessories from a renowned German manufacturer to clinics across Canada. By adding new products to our catalogue, Intriquip is making it easier for clinics across Canada to access trusted electrosurgical units, smoke evacuation systems, and high-quality accessories. And we’re not stopping there - we're continuing to expand our selection to better serve the needs of today’s veterinary and medical professionals, all with the support of our experienced Canadian team. “These advanced electrosurgical systems reflect decades of innovation and reliability, delivering precision and performance trusted by professionals,” said Garth Mathers, General Manager at Intriquip. “ We’re proud to offer their equipment as part of our expanded product selection and support clinicians with trusted solutions for veterinary and medical care across Canada. ” Highlighted products include: ARC 100 Electrosurgical Unit - Compact, easy to operate, and well-suited for general surgical needs SHE SHA Smoke Evacuation Unit - Quiet and effective, helping maintain clear air in surgical environments A wide range of accessories - Including Apexx Curve, Motic SMZ-161 Microscope, Pro2 Laser Therapy Unit, Zeus Laser Therapy Unit Now Available Through Intriquip Canadian professionals can now access these advanced products directly from Intriquip: ARC 100 Electrosurgical Unit SHE SHA Smoke Evacuation System Bowa ARC CART Trolley Intriquip’s dedicated Canadian team supports all products, ensuring fast shipping, responsive service, and expert product knowledge. “We know how important quality and support are when it comes to surgical tools,” added Garth Mathers. “This addition ensures our clients have access to reliable, clinically proven technology, without dealing with cross-border delays or uncertainty.” About Intriquip Instruments Inc. Intriquip has supported veterinary and medical professionals in Canada for over 30 years. Located in Emerald Park, Saskatchewan, the company offers a wide range of surgical equipment, monitoring devices, anesthesia systems, autoclaves, and more, backed by experienced technicians and personalized customer care. Contact Details Intriquip Instruments Inc. Garth Mathers +1 800-361-3777 sales@intriquip.com Company Website https://www.intriquip.com/

May 20, 2025 08:57 AM Eastern Daylight Time

Article thumbnail News Release

Laptop Power Without Limits Elvis Tech Rolls Out Innovative Solar Solutions for Off-Grid Independence

Rev Up Marketers

As Nigeria continues to face systemic electricity supply challenges, technology company Elvis Tech has announced the launch of a new line of solar-powered solutions aimed at providing reliable alternatives for individuals and small businesses. The newly available devices include solar laptop power banks, high-quality laptop power bank, and portable solar generators, specifically designed for off-grid and low-power environments. The move follows growing concerns over the impact of erratic grid power on productivity, education, and small-scale enterprise across the country. According to recent energy access reports, millions of Nigerians lack dependable electricity, with outages lasting hours or days in many urban and rural areas. In response, Elvis Tech’s solar-powered offerings are engineered to provide a stable source of power for essential digital and household tools. The company’s solutions require no fuel, emit no noise, and are equipped with lithium battery technology and smart charging systems to meet the evolving energy needs of users. “The inability to access electricity continues to undermine development across sectors,” said Elvis Ogbonna, Founder and Chief Executive Officer of Elvis Tech. “Our goal is to offer practical, scalable tools that allow people to stay connected, work remotely, and operate their businesses—regardless of the grid.” The company’s latest line of products includes long-lasting backup batteries compatible with most laptops, designed for maximum power efficiency and portability. Also available are solar-rechargeable models that provide power independence for users in remote or underserved areas—particularly beneficial for students, remote workers, and field professionals. In addition, Elvis Tech has introduced a compact, silent solar generator with energy storage capacities ranging from 510Wh to 1.9kWh. They are capable of powering key devices such as fans, routers, lighting systems, and other low-voltage appliances, offering a clean and practical alternative to standard fuel-powered generators. The rollout is part of its strategy to advance energy access through distributed, user-owned solutions. The company reports strong early demand for its pay-on-delivery model, which allows customers to verify product quality before purchase—an increasingly important trust factor in the Nigerian e-commerce landscape. About Elvis Tech Elvis Tech is a Nigerian-based energy technology company focused on addressing power access challenges through affordable, off-grid innovation.The company's portfolio, which includes portable solar generators, high-efficiency laptop power banks, and solar laptop power banks, helps people, students, and business owners obtain reliable access to electricity. Elvis Tech is promoting economic mobility and energy resilience through its dedication to dependability, accessibility, and local relevance. Contact Details Elvis Tech Limited Elvis Ogbonna +234 701 908 6644 info@elvistech.ng Company Website https://www.elvistech.ng/

May 20, 2025 07:37 AM Eastern Daylight Time

Article thumbnail News Release

4 Stocks To Watch In The $47 Billion Cellular Therapeutics Market

ADIA FATE DNA PLUR

Cell-based therapeutics have come a long way from simply experimental treatments confined in labs to their current mainstream commercial success. In the past year alone, the FDA approved seven new cell therapies, bringing the total number of gene and cell therapies approved in the US to 43, with the largest segment of these products being umbilical cord blood derivatives. Unlike other treatments, cell-based therapies use modified or healthy cells to treat or prevent disease, often by replacing damaged or malfunctioning cells. This makes cell-based therapies uniquely suited for various conditions like cancer treatments, autoimmune disorders, and tissue regeneration. Thanks to the rapidly advancing pace of innovation and cell therapy’s potential to transform across disease areas with significant unmet needs, market researchers project that the global cell therapy market could grow from about $7.43 billion in 2025 and reach around $47.72 billion by 2034, representing an impressive CAGR of 22.96% over the period. As such, a number of key players in the market have been generating considerable investor interest as they continue increasing market share. For instance: Adia Nutrition Inc. (OTCQB:ADIA) is on a mission to revolutionize healthcare and supplementation through innovative partnerships. The company operates two distinct divisions: Adia Labs, a supplement division providing premium, organic supplements, and Adia Med, its medical division responsible for establishing clinics that specialize in leading-edge stem cell therapies, most notably Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for treatments like Multiple Sclerosis (MS). Adia has recently been generating significant investor interest following an exciting start to the year with the announcement of several major corporate milestones. In May, the company announced that it had successfully uplisted from the OTC Pink Sheets to the OTCQB Venture Market, effectively enhancing its visibility and liquidity. The process was achieved in an unprecedented six weeks from the filing date of April 2nd, alongside the completion of SEC Rule 15c2-11 compliance. The OTCQB Venture Market and 15c2-11 compliance elevate Adia's ability to showcase its pioneering umbilical cord stem cell therapies and premium nutritional products to a wider investor base, potentially unlocking more shareholder value. The uplisting follows the successful completion of its independent audit, a crucial milestone that positioned the company for uplisting to the OTCQB. Earlier, Adia had announced a transformative overhaul of its share structure, including the retirement of approximately 15 million shares, reducing the outstanding common stock from about 95.9 million shares to 80.4 million shares, and the cancellation of a commitment agreement requiring the issuance of 10 million additional shares. Furthermore, the company recently revealed that Adia Labs had secured FDA registration for Adia Vita, one of its top-tier products featuring umbilical cord stem cells with a minimum of 100 million viable cells and 3 trillion exosomes per unit, in a move that would expand the reach of its regenerative treatments. By offering a superior product at a reduced price, Adia Med intends to differentiate itself from existing alternatives, thereby driving rapid client growth and making these therapies more accessible. At the beginning of the year, Adia set out an ambitious strategic expansion plan for Adia Med satellite locations across the United States. This initiative aimed to make Adia Med's innovative treatments more accessible by partnering with premier medical spas dedicated to anti-aging, wellness, and body repair. In line with this plan, the company announced the opening of its first satellite location in Tinton Falls, New Jersey. This was in partnership with Keep Glowing Medical Spa and renowned physician Dr. Michael Ellis, thus blending cutting-edge stem cell therapies with an established wellness hub. It is also important to note that Adia is in the process of registering with the State of Florida's Agency for Health Care Administration (AHCA), a crucial initiative designed to secure approval for accepting private insurance for the company’s stem cell therapies. Until now, Adia Med's operations have depended solely on out-of-pocket payments from patients. However, that approval could be a game changer since collaborating with private insurers would lift the financial barriers that currently restrict patient access. Unsurprisingly, several organizations and healthcare entities from various countries have reached out to Adia Med over recent months, expressing enthusiasm for establishing clinics that offer its cutting-edge treatments, including therapeutic plasma exchange (TPE), hematopoietic stem cell transplantation (HSCT), and umbilical cord blood stem cell (UCB-SC) therapies utilizing Adia Labs' premier product, Adia Vita. Fate Therapeutics (NASDAQ:FATE) is focused on developing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies. The company’s proprietary iPSC product platform is uniquely designed to facilitate the manufacture of engineered cell products, which can be stored in inventory for off-the-shelf availability and can be administered in combination with other therapies. This therefore allows it to overcome numerous limitations associated with patient- and donor-sourced cell therapies. FATE recently announced that the FDA had granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead product, FT819, illustrating the potential of cell-based therapies. FT819 is an investigational, off-the-shelf, iPSC-derived CAR T-cell therapy that is currently in Phase 1 clinical development for the treatment of active moderate to severe systemic lupus erythematosus (SLE), including lupus nephritis (LN). What the RMAT designation means is that the FDA recognizes the potential of off-the-shelf CAR T-cell therapy to address significant unmet needs and will enable increased dialogue with the FDA throughout the development process. The RMAT designation was established to expedite the development and review of regenerative medicine therapies for serious or life-threatening diseases or conditions. The designation includes all Breakthrough Therapy designation features, such as early interactions with the FDA, including discussions on potential surrogate or intermediate endpoints that may support accelerated approval and satisfy post-approval requirements, and potential priority review of a product’s biologics license application. Pluri Inc. (NASDAQ:PLUR) is a leading biotechnology company leveraging its proprietary platform to create cell-based solutions that will revolutionize everything from the way we treat illness to the way we eat. Pluri’s 3D cell expansion platforms can expand a single cell into billions of distinct cells quickly and reliably, in a highly cost-effective process that can be applied to various types of cells. The company recently achieved a significant milestone after the US Patent and Trademark Office (USPTO) issued a patent for its immune cell expansion technologies. The patent covers mucosal-associated invariant T (MAIT) cells, which play a crucial role in the body's defense against infection and support tissue repair. Pluri’s placental allogeneic MAIT cell platform facilitates the development of unconventional immune T cells that could be instrumental in treating solid tumors. This is important considering that despite revolutionary progress in blood cancers, equivalent success has yet to be duplicated in solid tumor malignancies, which present unique challenges. Pluri’s MAIT cells, which are isolated from human placentas, a source rich in highly potent allogeneic immune cells often overlooked in traditional therapies, offer substantial benefits compared to conventional T cells. Unlike conventional T cells typically collected from peripheral blood, Pluri’s MAIT cells demonstrate a lower alloreactivity profile. This characteristic not only minimizes their likelihood of inducing graft-versus-host disease (GvHD)—a significant advantage over other potential allogeneic products—but also suggests that they may persist in the body for a longer duration, enhancing their therapeutic efficacy. Ginkgo Bioworks (NYSE:DNA) is building one of the leading horizontal platforms for cell programming and biosecurity. This cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. The company recently reported its first-quarter earnings, with total revenue coming in at $48 million, up from $38 million in the comparable prior-year period. This reflected a 27% increase primarily due to $7 million of non-cash revenue from deferred revenue relating to the mutual termination of a customer agreement. Excluding the $7 million non-cash deferred revenue release, first-quarter cell engineering revenue was $31 million, up from $28 million in the prior-year period. During the earnings call, management reiterated that biotechnology remained a critical emerging technology area in the US and Ginkgo was well positioned to provide biosecurity and R&D services, as illustrated by its 28 US government projects across cell engineering and biosecurity with roughly $180 million of contracted backlog and unfunded potential backlog. In addition, the company noted that it had made significant progress on cost cutting while still serving its customers. Gingko revealed that it was on track for a $205 million reduction in its annual run rate between the first quarter of 2024 and the first quarter of this year. Cash, cash equivalents, and marketable securities balance as of the end of the period were $517 million. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by the company to assist in the production and distribution of content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com

May 20, 2025 06:00 AM Eastern Daylight Time

Article thumbnail News Release

ZenaTech’s (Nasdaq: ZENA) DaaS Model, Strategic Acquisitions Drive 92% Revenue Growth in Q1

ZENA

The commercial and military drone sectors are entering a high-growth phase, driven by rapid tech innovation and expanding use across industries. The global commercial drone market hit $30.02 billion in 2024 and is projected to grow at a 10.6% CAGR through 2030, per Grand View Research. Meanwhile, military drone spending is expected to more than double from $24.25 billion in 2025 to $56.69 billion by 2033, growing at 11.2% CAGR, according to Straits Research. With drones transforming agriculture, logistics, public safety, and defense, investors are scanning the skies for breakout players. ZenaTech (Nasdaq: ZENA) is an AI-driven drone and software company that is making strategic moves that position it as a rising force in this rapidly evolving sector. Diversified Drone Applications Fuel Growth ZenaTech has built a multi-vertical drone business through its subsidiary ZenaDrone, with solutions tailored for agriculture, infrastructure inspection, inventory management, public safety, and defense. The company’s AI-powered drones — including the ZenaDrone 1000 and its IQ Nano and IQ Square models — serve both indoor and outdoor use cases, enabling everything from 3D mapping and barcode scanning to power line inspections and real-time surveillance. A key differentiator is ZenaTech’s embrace of a Drone-as-a-Service (DaaS) model. Much like SaaS platforms or ride-hailing services, the company enables clients to access drones on a subscription or pay-per-use basis — no hardware purchases, pilots, or maintenance required. This recurring-revenue model lowers adoption barriers while providing scalable upside across multiple sectors and geographies. Poised to Capture Agricultural Sector Growth in Europe In early May, ZenaTech announced the opening of its European headquarters in Dublin, Ireland, a strategic move that places it near critical logistics infrastructure and opens access to high-growth EU markets. Europe’s agricultural drone market is projected to grow from $4.6 billion in 2023 to over $43 billion by 2032, a staggering 28.6% CAGR. Farmers across the continent are adopting drone technologies for seeding, spraying, monitoring, and data collection. ZenaTech is targeting this growth with specialized DaaS offerings for precision agriculture, renewable energy, and construction. According to CEO Shaun Passley, Ph.D., “our AI-powered drone solutions are designed to boost crop yields while reducing operational costs and provide smart, data-driven insights.” With favorable regulatory tailwinds and a continental focus on sustainability, ZenaTech is well-positioned to benefit from rising demand in this space. Launching Drone-Based Cleaning Services in Dubai One of the company’s most strategically significant initiatives is its recent expansion into Dubai, where it is launching a drone-based exterior building cleaning service. Leveraging the IQ Square, a large-format drone equipped with tethered water and power lines, ZenaTech aims to tap into a fast-growing niche. Dubai’s high-rise skyline, frequent sandstorms, and mandated cleaning standards create a natural use case for drone-enabled washing services. The global drone cleaning market is expected to triple from $4.36 billion in 2023 to $13.2 billion by 2030. As a first mover in this region, ZenaTech is looking to establish an early foothold in an emerging sector of urban infrastructure management. Advancing Defense and Proprietary Innovation ZenaTech is also developing its presence in defense, with its IQ Nano drone swarms designed for autonomous surveillance, RFID and barcode scanning, and battlefield logistics. These lightweight drones, available in compact 10x10 and 20x20-inch formats, are being tested for military and commercial use and are in the process of obtaining Blue UAS certification, enabling sales to U.S. government agencies. Vertical integration is another strength. Through its Taiwan-based Spider Vision Sensors subsidiary, ZenaTech has developed proprietary cameras that align with U.S. National Defense Authorization Act (NDAA) compliance requirements. Internal control over hardware development supports faster iteration and greater cost control across its product lines. Revenue Growth and Aggressive Scaling ZenaTech reported $1.13 million in Q1 2025 revenue, a 92% year-over-year increase. Much of this momentum stems from the DaaS segment, bolstered by a disciplined acquisition strategy. Recent purchases include Oregon’s Weddle Surveying and Florida’s KJM Land Surveying, both of which enhance its geospatial data and infrastructure services. In the enterprise software space, ZenaTech also acquired UK-based Othership, a SaaS workplace platform. The company has opened a drone testing facility in Turkey and expanded hiring in the UAE, Taiwan, and the United States to support R&D and manufacturing needs. While operating expenses rose meaningfully in the quarter, the company has signaled a long-term growth focus. Management also noted it is evaluating over 20 potential acquisitions within the next year, underscoring its ambitions to scale rapidly through both organic and inorganic strategies. Bottom Line As the global drone market accelerates, ZenaTech (Nasdaq: ZENA) is carving out a role as a nimble and diversified competitor. Its DaaS model enables recurring revenue and ease of customer adoption, while its international expansion, particularly into Europe and Dubai, offers near-term growth catalysts. With a strong product pipeline, proprietary innovations, strategic acquisitions, and accelerating revenue, ZenaTech may offer investors an intriguing early-stage opportunity in the broader drone revolution. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by the company to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com

May 20, 2025 06:00 AM Eastern Daylight Time

Article thumbnail News Release

Tether on TRON Surpasses $75 Billion, Tops All Stablecoin Activities

TRON DAO

May 19, 2025 - Geneva, Switzerland - TRON DAO announced today that the total circulating supply of Tether (USDT) on the TRON blockchain has surpassed $75 billion, once again making TRON the leading network for USDT. As the most widely adopted stablecoin, Tether represents more than 63 percent of the global market share with over $150 billion in circulation. Over 50 percent of that supply is issued on TRON - the #1 network among all blockchain networks for USDT total issuance, total transaction volume, and daily active users. As of May 2025, TRON supports over 8.3 million daily transactions and has surpassed 306 million user accounts on the blockchain. The network processes an average of $20 billion in daily USDT transfers. TRON leads in total transfer volume, facilitating nearly 29 percent of all stablecoin transaction value globally, reflecting its growing role as the preferred settlement network. TRON also leads in active user engagement with over 1 million unique accounts transacting USDT daily, accounting for 28 percent of all active stablecoin wallet addresses across blockchains. Accounting for over 55% of all USDT transaction volume, USDT on TRON continues to experience sustained and accelerating growth, reflecting rising global demand for efficient, low-cost, and reliable digital dollar infrastructure. This milestone reflects TRON's role in enabling a wide range of real-world financial use cases, from high-volume retail payments to institutional-scale transactions. As global demand for stablecoins grows, particularly for cross border settlement and financial access, TRON has become a trusted and widely adopted blockchain network, offering the scale, speed, and efficiency required to support stablecoin transactions at a global level. “TRON’s growth is driven by a strong alignment with the core values of the crypto industry, including financial freedom and individual empowerment,” said Justin Sun, founder of TRON. “USDT on TRON has become the preferred choice for millions of users around the world because it is fast, stable, and accessible. The focus remains on delivering real world utility and building strong network effects that make TRON the leading platform for stablecoin transactions.” The circulating supply of USDT grew by approximately 7 billion dollars in the first quarter of 2025, alongside an increase of 46 million user wallets. This growth reflects rising trust in Tether’s transparency and its role as a reliable representation of the U.S. dollar. It also reinforces USDT as a stable, efficient, and accessible on-ramp to the global economy. As TRON continues as the leading network for USDT, its ecosystem is evolving to meet the growing institutional demand for secure, scalable, and secure digital asset infrastructure. In April 2025, World Liberty Financial selected TRON to integrate their stablecoin, USD1. TRON and Tether have also deepened their commitment to financial integrity through the T3 Financial Crime Unit (T3 FCU), a joint initiative with TRM Labs. Since its launch, the T3 FCU has collaborated with global law enforcement agencies to freeze over $160 million in illicit funds. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON blockchain has experienced significant growth since its MainNet launch in May 2018. TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin, exceeding $75 billion. As of May 2025, the TRON blockchain has recorded over 306 million in total user accounts, more than 10 billion in total transactions, and over $23 billion in total value locked (TVL), based on TRONSCAN. TRONNetwork | TRONDAO | X | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Yeweon Park press@tron.network Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

May 19, 2025 05:38 PM Eastern Daylight Time

Image
Article thumbnail News Release

Dr. Rian Maercks of The Maercks Institute Shares Expert Insights on Midface Lifting with the American Society of Plastic Surgeons

The Maercks Institute

The recent surge in popularity of the "midface-lift" has ignited widespread interest among patients seeking the elusive secret behind the subtly refreshed, lifted appearance often seen on celebrities—without the telltale signs of surgery. As facial rejuvenation trends evolve, the American Society of Plastic Surgeons turned to Dr. Rian Maercks, founder and medical director of The Maercks Institute in Miami, for his unique insights on this highly discussed topic in the article: "The Mid-Facelift Is Taking Facial Aesthetics by Storm". Dr. Maercks, a board-certified plastic surgeon and internationally recognized innovator in aesthetic medicine, is known for challenging conventional surgical paradigms. His eponymous MAERCKS Lift—a signature deep-plane technique—delivers profound facial support with a remarkably natural aesthetic and minimal downtime, aligning perfectly with the desires of today’s sophisticated patients. At the core of Dr. Maercks’ philosophy is an unwavering commitment to harmony and nuance, prioritizing individualized, non-cookie-cutter outcomes that defy the “operated” look so common with more aggressive procedures. In the recent ASPS article, Dr. Maercks cautions against superficial and overly simplistic approaches to midface rejuvenation. “True midface support is not about pulling skin tight—it’s about restoring the underlying architecture in a way that respects natural human anatomy,” he explains. The MAERCKS Lift accomplishes this by engaging deep structures of the face to restore youthful volume and positioning, without the conspicuous markers of surgery. However, Dr. Maercks emphasizes that focusing solely on the midface can result in aesthetic imbalance. “Facial features must work together cohesively. Neglecting adjacent areas—such as the neck—can create visual dissonance that undermines the overall result,” he notes. To address this, he frequently incorporates minimally invasive techniques such as MicroLyft™ or lateral platysmaplasty, enhancing jawline and neck definition without significantly extending recovery time. A Thoughtful Alternative to Traditional Facelifts Midface lifting has traditionally been one of the more complex aspects of facial rejuvenation, requiring surgical precision and an artistic eye. The Maercks Institute has become a trusted destination for discerning patients seeking advanced facial aesthetic care with a preference for refined, understated outcomes. Unlike standard procedures that often rely on skin tightening alone, Dr. Maercks' methodology restores facial harmony by lifting and re-supporting deeper facial layers in a natural vector of aging reversal. About Dr. Rian Maercks and The Maercks Institute Dr. Maercks completed his training in plastic and reconstructive surgery at the prestigious Duke University Medical Center and has since become a thought leader in aesthetic innovation, contributing to both clinical advancement and patient education. The Maercks Institute, located in the heart of Miami, serves a global clientele and is renowned for delivering elegant, natural results in facial rejuvenation, body contouring, and non-invasive procedures. Dr. Maercks’ thoughtful, evidence-based approach continues to attract patients who are not only seeking aesthetic enhancement but are also deeply concerned with preserving their identity and individuality. Discover the Maercks Difference As more individuals seek facial enhancement without overt signs of surgery or prolonged recovery, The Maercks Institute stands as a beacon of integrity and excellence in aesthetic medicine. Dr. Maercks invites patients interested in midface lifting, facelifting, or comprehensive facial rejuvenation to schedule a private consultation and explore the personalized, high-touch care that defines the Maercks experience. For more information or to book a consultation, visit www.themaercksinstitute.com or call (305) 328-8256. Contact Details Courtney Daniels Consulting Courtney Daniels courtney@cocodaniels.com Company Website https://www.themaercksinstitute.com/

May 19, 2025 10:00 AM Eastern Daylight Time

Article thumbnail News Release

Sea Tow Foundation™ Releases Third Video in the "Sober Skipper™: Why It Matters" Series Featuring Professional Wakeboarder, Thomas Herman

Sea Tow Foundation

The Sea Tow Foundation ™, a nonprofit dedicated to promoting boating safety, has launched the last video in its " Sober Skipper™: Why It Matters " series, featuring professional wakeboarder, Thomas Herman. Released in conjunction with National Safe Boating Week, the new video highlights the critical role of a Sober Skipper in ensuring a safe and enjoyable experience on the water. The video series is part of the Foundation’s ongoing campaign to eliminate accidents and fatalities due to Boating Under the Influence (BUI). The campaign targets men ages 24-50, the group identified by U.S. Coast Guard statistics as most at risk for BUI-related incidents. As a professional athlete, Herman shares why staying sober on the water is essential – for safety and for peak performance. He emphasizes the importance of having a Sober Skipper behind the wheel, ensuring that wakeboarders, water sports enthusiasts and recreational boaters alike can focus on their time on the water without worrying about unnecessary risks. National Safe Boating Week is held the week prior to Memorial Day weekend (May 17-23, 2025) to reach and educate boaters at the start of the summer boating season. This year, the Sea Tow Foundation is amplifying the Sober Skipper message with the launch of the video. "Wakeboarding, like all water sports, requires focus, control and quick decision-making," said Gail R. Kulp, Executive Director of the Sea Tow Foundation. "National Safe Boating Week is the perfect time to remind all boaters and water sports enthusiasts that responsible choices—like designating a Sober Skipper—can prevent tragedies and make every boating experience safer and more enjoyable. Thomas Herman’s message reinforces the importance of making safety a priority on the water." Watch "Sober Skipper: Why It Matters to Thomas Herman" now and join the Sea Tow Foundation in this important mission: https://www.boatingsafety.com/page/Why-It-Matters ABOUT SEA TOW FOUNDATION The Sea Tow Foundation – a 501(c)(3) nonprofit organization – was started in 2007 by Captain Joe Frohnhoefer, founder of Sea Tow Services International, after he witnessed too many preventable accidents and fatalities on the water. Through its flagship programs, which include the Life Jacket Loaner Program, Sober Skipper Campaign, Flare Education and the National Boating Safety Awards, the Sea Tow Foundation strives towards its vision of a world where boaters are safe and responsible. To learn more, visit boatingsafety.com. Contact Details Keaveny Hewitt +1 919-622-5276 khewitt@onwrdupwrd.com Company Website https://www.boatingsafety.com/

May 19, 2025 10:00 AM Eastern Daylight Time

Article thumbnail News Release

Giant Mining Advances Majuba Hill with Completion of 5,484.5 Ft Spring 2025 Drill Program

Giant Mining Corp.

VANCOUVER, BC — May 19, 2025 — Giant Mining Corp. (CSE: BFG | OTC: BFGFF | FWB: YW5) (CSE:BFG.WT.A) (“Giant Mining” or the “Company”) is pleased to announce the successful completion of Phase 1 of its 2025 spring diamond core drilling program ( "Core Program" ) at the Majuba Hill Porphyry Copper-Silver-Gold Project ( "Majuba Hill" ) in Pershing County, Nevada. Equipment demobilization has concluded, and the Company is now preparing for comprehensive analysis of drill core samples, aiming to define geological controls and further delineate mineralization. A total of five drill holes, MHB-32 through MHB-36, were completed for a combined 5,484.5 feet (1,671.68 meters) of core drilling. This brings the cumulative total of drilling at Majuba Hill to 89,395 feet (27,247.5 meters), which will significantly enhance the Company’s geological model and support future deposit development. Table 1: Majuba Hill 2025 Drill Program Collar Details The primary objective of the Core Program was to step out from and expand the known zones of copper mineralization and advance the Majuba Hill Project toward completing a Mineral Resource Estimate ( “MRE” ). All drill core was transported to Giant Mining’s secure core facility in Elko, Nevada, where it was logged, sawn, and sampled by Company personnel. The samples were submitted to ALS Global Services ( “ALS Labs” ) for geochemical analysis, with sample preparation completed at their Elko facility and final assaying conducted at their laboratory in Vancouver, British Columbia. David Greenway, CEO of Giant Mining, commented: “The 2025 drill season has been our most exciting and technically ambitious to date. We began the program with strong visual mineralization that exceeded expectations, prompting us to add a fifth drill hole—MHB-36—guided by AI-assisted geophysical modeling. This AI-predicted target intersected promising mineralization, suggesting a potential new discovery and was a meaningful step-out from previously defined zones. Notably, MHB-33 was drilled to a depth of 1,963 feet and encountered significant native copper, expanding our understanding of the scale and potential of the Majuba Hill Copper-Silver-Gold system. We now eagerly await assay results from ALS Labs as we work toward completing an NI 43-101 Mineral Resource Estimate to support future development plans.” Key highlights include: MHB-32 – Starting with a Bang Core Hole MHB-32 was completed to a total depth of 889.5 feet (271.1 meters). The hole intersected copper-bearing magmatic-hydrothermal breccias with secondary copper minerals, including azurite, malachite, and chalcocite. These transitioned into strongly oxidized copper sulfides, with primary, unoxidized chalcopyrite near the bottom of the hole. Click Image To View Full Size Figure 1: MHB-32 - Azurite, malachite, chalcocite in magmatic-hydrothermal breccia at 527 to 537 ft (160.-163. m). This early success confirmed the vertical continuity of the mineralized system and the presence of high-potential breccia-hosted copper zones. Click Image To View Full Size Figure 2: MHB-32 – Clast of intrusive with chalcopyrite in tourmaline/chalcopyrite matrix breccia at 810 ft (246.89 m). MHB 34 – Native Copper Encounter Core Hole MHB-34 was drilled to a total depth of 1,963 feet (598.3 meters). The hole encountered persistent native copper, cuprite, and chalcopyrite mineralization in its deeper sections, with native copper observed beyond 1,850 feet. Click Image To View Full Size Figure 1: MHB-34 at 1,499 ft (456.9 m) Native Cu on fracture HQ Core, 2.5-inch (63.5 mm) diam. These results indicate a robust porphyry system at depth and suggest proximity to a primary copper sulfide source. MHB 36 – An A.I. Driven Step Out Discovery and Potential Deposit Extension Click Image To View Full Size   The fifth and final drill hole of the Core Program, MHB-36, was planned for a total depth (TD) of 1,000 feet (304.8 meters). This hole was designed by Exploration Technologies ( “ExploreTech” ) using its proprietary AI-assisted geophysical modeling system to test a high-potential resistivity anomaly delineated in the southern sector of the Majuba Hill project area. The AI-driven targeting approach aimed to identify geologically favorable zones with potential for new copper mineralization beyond the existing mineralization footprint. Figure 2: 3D Model of Majuba Hill, showing the five drill collars and summarized results for MHB-36. Right: Downhole plot of drilling results and ExploreTech prediction, showing predicted probability of sulfide mineralization and the true intersection (dashed grey). Due to the intersection of the sulfides predicted by modeling the hole was extended to 1100 feet (335.28 meters). MHB-36 intersected disseminated and vein-hosted chalcopyrite mineralization within intrusive and magmatic hydrothermal breccias, beginning at a downhole depth of 650 feet (198 meters). Mineralization was observed intermittently beyond 905 feet (274.32 meters), confirming the accuracy of the AI model and highlighting the potential for further extensions of copper-bearing zones in this underexplored area. Click Image To View Full Size Figure 3: MHB-36/935 feet (285 m). Disseminated chalcopyrite in Intrusive. Majuba Hill’s critically important characteristics are as follows:   Quality Assurance/Quality Control (“QA/QC”) Measures, Chain of Custody The Company utilizes a QA/QC program using best industry practices at the Majuba Hill Project. The samples are placed in cloth sample bags and are transported from the Giant Mining secure warehouse to the ALS Labs Sample Prep Facility in Elko, Nevada. ALS Labs then securely transports the prepared pulps to their analytical lab in North Vancouver, B.C. Drill core samples are sawn in half lengthwise and one half is placed in labeled cloth sample bags. All samples are analyzed for copper, gold, silver, and 33 other elements. Gold is determined by ALS Labs method Au-AA23 which is a fire assay with an AAS finish on a 30-gram split. Copper, silver, and the remaining 31 elements are determined by ALS Labs method ME-ICP61 which is a four-acid digestion and ICP-AES assay. Approximately 5% of the submitted samples are drill duplicates and copper-gold-porphyry commercial standard reference material pulps. The remaining pulps will be retrieved from ALS Labs. Qualified Person The scientific and technical information contained in this news release has been reviewed and approved by E.L. “Buster” Hunsaker III, CPG 8137, a non-independent consulting geologist who is a “Qualified Person” as such term is defined under  National Instrument 43-101 – Standards of Disclosure for Mineral Projects ( “NI 43- 101” ). About Giant Mining Corp. Giant Mining is focused on identifying, acquiring, and advancing late-stage copper and copper/silver/gold projects to meet the growing global demand for critical metals. This demand is driven by initiatives like the Green New Deal in the United States and similar climate-focused programs worldwide, which require substantial amounts of copper, silver, and gold for electric vehicles, renewable energy infrastructure, and the modernization of clean and affordable energy systems. The Company’s flagship asset is the Majuba Hill Copper, Silver, and Gold District, located 156 miles (251 km) from Reno, Nevada. Majuba Hill is situated in a mining-friendly jurisdiction with supportive regulations and has the potential to become one of the next major copper deposits, critical for meeting the increasing need for this red metal. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. On Behalf of the Board of Giant Mining Corp. “David Greenway” David C. Greenway President & CEO For further information, please contact: E: info@giantminingcorp.com P: 1 (236) 788-0643      VISIT OUR WEBSITE FOR MORE DETAILS www.giantminingcorp.com LIKE AND FOLLOW Instagram, Facebook, Twitter, LinkedIn   DOWNLOAD INVESTOR INFORMATION Click Here      Forward-Looking Statements This news release contains certain forward ‐ looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward ‐ looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward ‐ looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward ‐ looking statements, whether as a result of new information, future events or otherwise. ###

May 19, 2025 09:56 AM Eastern Daylight Time

Image
Article thumbnail News Release

Market Alert: DarioHealth Receives $3 Price Target and Buy Rating: Everything You Need to Know

Global Markets News

Litchfield Hills Research has initiated coverage of DarioHealth Corp. (NASDAQ: DRIO)* with a Buy rating and a $3 price target, representing potential upside of over 350% from current trading levels of around $0.66 per share. This bullish outlook comes as the digital health company continues to transform its business model and expand its comprehensive chronic care platform. DarioHealth has successfully pivoted from a direct-to-consumer model to a B2B2C (business-to-business-to-consumer) approach since 2020. This strategic shift has allowed the company to leverage its consumer platform strengths while expanding sales to health plans and employers. The company's B2B2C recurring revenue grew by an impressive 398% year-over-year in Q4 2024, demonstrating strong market adoption. The analyst highlights Dario's proven track record of both organic growth and strategic acquisitions, including the recent Twill acquisition which has strengthened its multi-condition platform. This expansion has positioned Dario to address five of the most common, expensive chronic conditions through a single, integrated solution. The $3 price target is based on a discounted future earnings model with a 9% discount rate. The analysis assumes Dario will reach GAAP breakeven in the second half of 2026, continue strong revenue growth to reach $66.1 million in 2026, achieve non-GAAP operating income of $17.4 million in 2026, and show improving gross margins, exceeding 80% in its core B2B2C business. Importantly, the report demonstrates that even at the $3 target price, Dario would trade at approximately 2.2x projected 2026 sales, which is still below the peer average of 2.28x. The analyst suggests Dario should command a premium multiple given its high growth profile and comprehensive platform. The report highlights Dario's unique competitive advantages relative to peers in the digital health space. Unlike competitors who focus on single conditions, Dario offers a comprehensive platform addressing diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. When comparing current market cap to sales and enterprise value to sales multiples, Dario trades at substantial discounts – 81% below peers on market cap to sales ratio and 54% below peers on enterprise value to sales ratio. This valuation gap, combined with Dario's proven clinical outcomes and expanding market presence, forms the core of the analyst's bull case. A significant growth driver highlighted in the report is Dario's expansion into the GLP-1 weight management space. The company's research has shown that members using GLP-1 experienced significant reductions in blood glucose levels in the first five months with changes sustained throughout the year. With the GLP-1 market projected to reach $100 billion by 2030, Dario's comprehensive solution combining medication management with behavioral support positions it to capture market share in this rapidly growing segment. Strategic partnerships, including its recent collaboration with Rula Health, further strengthen Dario's offering by providing access to over 15,000 behavioral health providers nationwide. The company is also leveraging AI technology to reduce operating expenses, with projections suggesting a 20% reduction in expenses between Q4 2024 and Q4 2025 through AI-driven process optimization. Litchfield Hills projects Dario's revenue will grow to $35.9 million in 2025 and $66.1 million in 2026, with gross margins improving to nearly 70% by 2026. The company is expected to achieve operational cash flow breakeven by late 2025, with full profitability in the second half of 2026. The recent $25.6 million private placement has strengthened Dario's balance sheet, providing sufficient runway to execute its strategic plan. With a blue-chip client list that includes major employers like Amazon, Microsoft, and Google, as well as top insurers and pharmaceutical companies, Dario appears well-positioned to capitalize on the growing demand for integrated digital health solutions that deliver measurable clinical outcomes and positive ROI. Recent News from Dario: DarioHealth Reports First Quarter 2025 Financial and Operating Results Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives * Legal Disclaimer & Disclosure: Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by the Wall Street Wire platform & media network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This article contains paid promotional content related to DarioHealth and was produced as part of their paid subscription to Wall Street Wire, which includes a monthly fee of five thousand US dollars paid in cash in return for promotional content and distribution services. The operators also receive additional fees for non promotional advisory and data services. DarioHealth did not necessarily review or approve this content prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. We are not responsible for third party analyst price targets are refer to them based on publicly availble reports. Additional or competing price target may exist and readers are advised to refer to the full report and its respective disclaimers and disclosures. Contact Details Wall Street Wire Network media.globalmarkets@gmail.com

May 19, 2025 07:51 AM Eastern Daylight Time

1 ... 45678 ... 3880